Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 16, 2024 10:01 ET | Source: Faron Pharmaceuticals Oy

Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024

Dr. Markku Jalkanen and Dr. Sirpa Jalkanen, Faron’s co-founders, have been nominated as one of three finalists in the ‘SMEs’ category of prestigious European Patent Office AwardsNominated in...
April 16, 2024 02:00 ET | Source: Faron Pharmaceuticals Oy

Faron Confirms Plans for the Coming Months Under New Leadership

Initial data from ongoing Phase 2 part of BEXMAB trial anticipated next monthIncoming CEO, Juho Jalkanen, to accelerate discussions with US regulator to coordinate plans for obtaining marketing...
March 18, 2024 09:00 ET | Source: Faron Pharmaceuticals Oy

Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML

Key highlights Latest readout of the BEXMAB study shows more responding patients and good durability of remission amongst HR HMA-failed MDS patients.4/5 of the initial Phase 1 HR HMA-failed MDS...
March 14, 2024 03:00 ET | Source: Faron Pharmaceuticals Oy

Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab

TURKU, Finland and BOSTON, March 14, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to...
March 13, 2024 03:00 ET | Source: Faron Pharmaceuticals Oy

Faron’s Financial Statement Release January 1 to December 31, 2023

TURKU, Finland and BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. ("Faron" or "the Company") (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company...
January 25, 2024 02:00 ET | Source: Faron Pharmaceuticals Oy

Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population

TURKU, Finland and BOSTON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to...
January 09, 2024 02:00 ET | Source: Faron Pharmaceuticals Oy

Inside information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trial

Phase 2 of the trial aims to recruit 32 patients with HMA-failed MDS and to provide final and optimized dosing for registrational studyCompany is exploring further development opportunities within the...
January 03, 2024 02:00 ET | Source: Faron Pharmaceuticals Oy

Faron Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

TURKU, Finland and BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Oy (“Faron” or “Company”) (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company pursuing a...
December 11, 2023 02:00 ET | Source: Faron Pharmaceuticals Oy

Inside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) Annual Meeting

Significant overall Response Rate (ORR) achieved in both HR-MDS (5/5) and HMA-failed MDS (5/5) patients The vast majority of responses are deep and durable with 7/10 MDS patients achieving CR/mCR...
December 07, 2023 02:00 ET | Source: Faron Pharmaceuticals Oy

Faron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine

Bexmarilimab monotherapy shows efficacy in achieving disease control and prolonged survival in late-stage metastatic solid tumorsCLEVER-1 targeting is safe and well-tolerated with no serious adverse...